clinical trial · NCT07821944
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 150
HyperlipidemiaHypercholesterolemiaEnlicitide DecanoatePlacebo
brief summary
Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol." The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.
started
Oct 15, 2026
primary completion
Nov 26, 2027
completion
Nov 26, 2027
last updated
Nov 2, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate in Adults With Hyperlipidemia in India
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol